Weight loss and diet management is a challenge for millions of people around the world. Ecumenically, more than 1 billion people are above an ideal weight. More than 100 million people in the Cumulated States are actively involved in a weight loss or weight management plan at any one time throughout the year. According to Grand View Research, the ecumenical extravagant corpulence treatment market was valued at USD 3.9 billion in 2015 and is expected to reach $15.6 billion by 2024. According to the Institute of Health Metrics and Evaluation, about 30% of the ecumenical population is either exorbitantly corpulent or extravagantly corpulent. In additament, incrementing cognizance of inordinate corpulence's impacts on health further drives the magnification of the market. The report denoted that the North American region holds the most sizably voluminous market quota of ecumenical extravagant corpulence treatment market due to growing inordinately corpulent and inordinately corpulent population. the commercial weight loss programs segment of the extravagant corpulence market is estimated to have grown 9.4 percent to $3.03 billion in 2017. John LaRosa, the Research Director of Marketdata, verbally expressed: "The number of active dieters is estimated to have fallen 10% since 2015, to 97 million, due to a growing size acceptance kineticism and dieter fatigue. More than 100 million people in the Cumulated States are actively involved in a weight loss or weight management plan at any one time throughout the year. Key market players in the ecumenical anti-inordinate corpulence market are Bristol-Myers Squibb, Eisai Company, FlaxoSithKline plc, Novo Nordisk, Alizyme, BoehringerIngelheim GmbH, Pfizer, Takeda Pharmaceutical, Rhythm Pharmaceuticals, Shionogi USA, Vivus, Zafgen and Norgine Pharmaceuticals Ltd. Ecumenical Exorbitant corpulence Management Market was about US$ 4.17 billion in 2015 and is expected to reach US$ 6.2 billion by 2022 at a CAGR of 8.2%.

Why you should be Interested:

The Obesity 2020 Conference is the premier event for Obesity Treatments in Barcelona and will provide valuable opportunities for connecting with key influencers.

Benefits in attending:

• To foster discussions, share expertise and exchange knowledge and best practices at all levels of the healthcare spectrum

• To encourage collaboration and enhance interactions at a global level

• Meet a range of specialists actively practicing in the field

• Strengthen your profile and position your organization as a key industry figure

• Develop new partnerships and networks with key decision makers/influencers

• Open doors for your organization to connect and develop strategic relationships in a neutral and relaxed sales environment

• Get access to targeted audience

• Brand Exposure – Promote your company’s message, products and services through a national Conference marketing campaign

• First hand live demonstrations to delegates

• To showcase new healthcare technologies and solutions in an intimate setting focused specifically on diabetes, obesity, Diet and nutrition

Why Sponsor /Exhibitors Obesity 2020?

Your sponsorship/Exhibition will give your organization fantastic exposure to around 150 attendees, and offers a unique opportunity to align your brand with this very highly successful, high profile event.

Obesity 2020 will provide a terrific and diverse platform to interact and network with fellow industry colleagues.

2020 Highlights:

• 150 Participation (70 Industry: 30 Academia)

• 10+ Keynote Speakers

• 50+ Plenary Speakers

• 05+ Exhibitors

• 12 Innovative Educational Sessions

• 5+ Workshops

• B2B Meetings

Target Audience:

• Directors, CEO’s of Organizations

• Business Development Managers

• Chief Scientific Officers

• R&D Researchers from Pharma Industries

• Professors, Associate Professors, Assistant Professors

• PhD Scholars

• Association, Association presidents and professionals

• Noble laureates in Health Care and Medicine

• Research Institutes and members

• Manufacturing Companies

• Training Institutes